Lumos PharmaNASDAQ: LUMO

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Lumos Pharma Inc. ( NYSE: LUMO ) , relating to its proposed merger with Double Point Ventures LLC. Under the terms of the agreement, Double Point Ventures will acquire Lumos Pharma's outstanding shares of common stock for $4.25 per share in cash, plus one non-transferable unsecured Contingent Value Right per share payable on achievement of certain milestones.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Lumos Pharma, Inc. (NASDAQ: LUMO) to Double Point Ventures LLC for $4.25 per share in cash, plus one non-transferable, unsecured Contingent Value Right per share payable on achievement of certain milestones, is fair to Lumos shareholders. Halper Sadeh encourages Lumos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper.

AUSTIN, Texas, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, or APPES 2024, to be held October 2-5, 2024 in New Delhi, India. This analysis of data from the OraGrowtH210 Trial evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on October 3rd by Professor Paul Hofman, MD, Liggins Institute, University of Auckland, Auckland, New Zealand.

Following Positive End of Phase 2 Meeting with FDA, Company Continues to Advance Plans for Phase 3 Placebo-Controlled Trial of LUM-201 in Moderate Pediatric Growth Hormone Deficiency

Lumos Pharma (LUMO) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $0.86 per share a year ago.

AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced that the Company will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th – 13th and the Cantor Global Healthcare Conference 2023 being held September 26th – 28th in New York City. Lumos Pharma management will present and host one-on-one meetings at both conferences.

Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Lisa Miller – Senior Director of Investor Relations Rick Hawkins – Chief Executive Officer and Chairman Lori Lawley – Chief Financial Officer John McKew – President and Chief Scientific Officer Duke Pitukcheewanont – Senior Vice President of Global Clinical Development and Medical Affairs Conference Call Participants Yasmeen Rahimi – Piper Sandler Leland Gershell – Oppenheimer Ed White – H.C. Wainwright Catherine Novack – Jones Trading Pete Stavropoulos – Cantor Fitzgerald Operator Good afternoon, and welcome to Lumos Pharma's Q2 2023 Financial Results Conference Call.